Durect Corp
(FRA:DC8A)
€
1.35
-0.01 (-0.74%)
Market Cap: 43.49 Mil
Enterprise Value: 40.63 Mil
PE Ratio: 0
PB Ratio: 5.62
GF Score: 53/100 - Q1 2024 DURECT Corp Earnings Call TranscriptMay 13, 2024€0.95 (+1.60%)Earnings
- Q4 2023 DURECT Corp Earnings Call TranscriptMar 27, 2024€1.15 (+1.77%)Earnings
- Q3 2023 DURECT Corp Earnings Call TranscriptNov 13, 2023Earnings
- DURECT Corp Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol TranscriptNov 07, 2023
- DURECT Corp at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Q2 2023 DURECT Corp Earnings Call TranscriptAug 09, 2023€2.82 (-0.70%)Earnings
- Q1 2023 DURECT Corp Earnings Call TranscriptMay 08, 2023€4.3 (+10.82%)Earnings
- DURECT Corp at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- DURECT Corp at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- Q4 2022 DURECT Corp Earnings Call TranscriptMar 07, 2023€4.56 (+2.24%)Earnings
- Q3 2022 DURECT Corp Earnings Call TranscriptNov 02, 2022€6.15 (-1.60%)Earnings
- Q2 2022 DURECT Corp Earnings Call TranscriptAug 04, 2022€5.7 (+8.57%)Earnings
- DURECT Corp Annual Shareholders Meeting TranscriptJun 15, 2022
- Q1 2022 DURECT Corp Earnings Call TranscriptMay 04, 2022€4.06 (+2.01%)Earnings
- Q4 2021 DURECT Corp Earnings Call TranscriptMar 07, 2022€5.6 (-3.45%)Earnings
- DURECT Corp To Discuss Agreement Call TranscriptDec 22, 2021
- Q3 2021 DURECT Corp Earnings Call TranscriptNov 02, 2021€10.9Earnings
- DURECT Corp at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Q2 2021 DURECT Corp Earnings Call TranscriptJul 29, 2021€11.8 (+2.61%)Earnings
- DURECT Corp Annual Shareholders Meeting TranscriptJun 15, 2021
- Q1 2021 DURECT Corp Earnings Call TranscriptMay 04, 2021€15.6 (-1.27%)Earnings
- Q4 2020 DURECT Corp Earnings Call TranscriptMar 04, 2021€17.6 (-7.85%)Earnings
- DURECT Corporation - Special Call TranscriptFeb 02, 2021
- DURECT Corporation - Special Call TranscriptNov 20, 2020
- Q3 2020 DURECT Corp Earnings Call TranscriptNov 02, 2020€15.4 (-0.65%)Earnings
- DURECT Corporation - Special Call TranscriptAug 27, 2020
- DURECT Corp DURECT Corporation Summary TranscriptAug 06, 2020
- Q2 2020 DURECT Corp Earnings Call TranscriptAug 03, 2020€17.2 (-1.15%)Earnings
- DURECT Corp Annual Shareholders Meeting TranscriptJun 17, 2020
- Q1 2020 DURECT Corp Earnings Call TranscriptMay 11, 2020€21 (+8.81%)Earnings
- Q4 2019 DURECT Corp Earnings Call TranscriptMar 03, 2020€17.5 (+6.71%)Earnings
- DURECT Corporation - Special Call TranscriptNov 12, 2019
- Q3 2019 DURECT Corp Earnings Call TranscriptNov 04, 2019€17 (+4.94%)Earnings
- Q2 2019 DURECT Corp Earnings Call TranscriptAug 01, 2019€9.64 (+0.88%)Earnings
- Q1 2019 DURECT Corp Earnings Call TranscriptMay 08, 2019€6.56 (-4.29%)Earnings
- DURECT Corporation Key Opinion Leader Call on NASH TranscriptApr 17, 2019
- DURECT Corporation Key Opinion Leader Call on Psoriasis TranscriptMar 29, 2019
- Q4 2018 DURECT Corp Earnings Call TranscriptMar 07, 2019€6.3 (-6.25%)Earnings
- DURECT Corporation - Special Call TranscriptFeb 27, 2019
DURECT Corp at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 02:00PM GMT
Release Date Price:
€3.74
(-2.60%)
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Great. Welcome, everyone. And our next presenting company is DURECT. I'm very pleased to have with us members of the senior management team. To my right is CEO, Jim Brown; and to my left is CFO, Tim Papp. Jim, Tim, thank you so much for joining us.
Tim Papp
DURECT Corporation - CFO
Thank you, Ed.
Jim Brown
DURECT Corporation - President & CEO
Thanks, Ed. It's great to see you.
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Yeah. So I wanted to start by just asking if you could provide a brief overview of the company and the current status of both your marketed and development programs.
Jim Brown
DURECT Corporation - President & CEO
Sure. Now, we -- as a company, we are focused on developing products that regulate the epigenome. And we have a history of once upon a time, we started as a company and especially the pharma space with drug delivery.
So we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)